Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer Academic Article uri icon

Overview

MeSH Major

  • Adenocarcinoma, Clear Cell
  • Antineoplastic Agents, Phytogenic
  • Carcinoma, Endometrioid
  • Cystadenocarcinoma, Mucinous
  • Cystadenocarcinoma, Papillary
  • Neoplasm Recurrence, Local
  • Ovarian Neoplasms
  • Paclitaxel

abstract

  • (1) Paclitaxel administered as a 1-hour infusion is well tolerated; (2) this schedule of administration does not result in cumulative myelosuppression; and (3) this schedule of administration results in dose-intensive paclitaxel delivery with a favorable toxicity profile.

publication date

  • January 1997

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 8996141

Additional Document Info

start page

  • 187

end page

  • 92

volume

  • 15

number

  • 1